$20 Billion is the total value of FARALLON CAPITAL MANAGEMENT LLC's 159 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 115.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SPY | Buy | SPDR S&P 500 ETF TRput | $3,719,076,000 | +16.5% | 8,700,000 | +20.8% | 18.64% | +12.5% |
| ATVI | Buy | ACTIVISION BLIZZARD INC | $1,902,561,600 | +363.9% | 20,320,000 | +317.7% | 9.54% | +347.7% |
| UNH | Buy | UNITEDHEALTH GROUP INC | $678,992,673 | +12.2% | 1,346,700 | +7.0% | 3.40% | +8.3% |
| CRM | Buy | SALESFORCE INC | $512,148,874 | +24.7% | 2,525,638 | +29.9% | 2.57% | +20.3% |
| CHTR | New | CHARTER COMMUNICATIONS INC Ncl a | $488,789,999 | – | 1,111,341 | +100.0% | 2.45% | – |
| MSFT | Buy | MICROSOFT CORP | $426,002,954 | +45.3% | 1,349,178 | +56.7% | 2.14% | +40.2% |
| ARMK | Buy | ARAMARK | $421,126,140 | -10.1% | 12,136,200 | +11.5% | 2.11% | -13.3% |
| WAB | Buy | WABTEC | $346,020,115 | -2.7% | 3,256,047 | +0.4% | 1.73% | -6.1% |
| CBRE | New | CBRE GROUP INCcl a | $333,875,858 | – | 4,520,388 | +100.0% | 1.67% | – |
| CSGP | Buy | COSTAR GROUP INC | $214,281,358 | -12.5% | 2,786,856 | +1.3% | 1.07% | -15.5% |
| HUM | Buy | HUMANA INC | $177,317,566 | +53.4% | 364,461 | +41.0% | 0.89% | +48.2% |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $166,701,744 | +20.8% | 1,375,200 | +14.1% | 0.84% | +16.6% |
| LNTH | Buy | LANTHEUS HLDGS INC | $111,063,780 | -2.7% | 1,598,500 | +17.5% | 0.56% | -6.1% |
| BEAM | Buy | BEAM THERAPEUTICS INC | $107,788,228 | -1.9% | 4,481,839 | +30.2% | 0.54% | -5.4% |
| CI | Buy | THE CIGNA GROUP | $104,701,620 | +71.2% | 366,000 | +67.9% | 0.52% | +65.1% |
| NTRA | Buy | NATERA INC | $100,796,323 | +56.4% | 2,277,883 | +72.0% | 0.50% | +50.7% |
| RVMD | Buy | REVOLUTION MEDICINES INC | $92,049,286 | +23.6% | 3,325,480 | +19.5% | 0.46% | +19.1% |
| PTGX | Buy | PROTAGONIST THERAPEUTICS INC | $90,846,452 | -27.1% | 5,446,430 | +20.7% | 0.46% | -29.7% |
| PACB | Buy | PACIFIC BIOSCIENCES CALIF IN | $85,371,402 | -23.0% | 10,224,120 | +22.6% | 0.43% | -25.7% |
| Buy | SUNRUN INCnote 2/0 | $85,075,850 | +16.4% | 117,346,000 | +15.8% | 0.43% | +12.1% | |
| INSP | Buy | INSPIRE MED SYS INC | $84,554,490 | -19.4% | 426,096 | +31.9% | 0.42% | -22.2% |
| VRTX | New | VERTEX PHARMACEUTICALS INC | $70,243,480 | – | 202,000 | +100.0% | 0.35% | – |
| AGIO | Buy | AGIOS PHARMACEUTICALS INC | $68,083,018 | -10.6% | 2,750,829 | +2.3% | 0.34% | -13.7% |
| THC | Buy | TENET HEALTHCARE CORP | $67,866,700 | +10.9% | 1,030,000 | +37.0% | 0.34% | +6.9% |
| SIMO | Buy | SILICON MOTION TECHNOLOGY COsponsored adr | $53,556,250 | -20.3% | 1,045,000 | +11.8% | 0.27% | -23.2% |
| DXCM | New | DEXCOM INC | $50,755,200 | – | 544,000 | +100.0% | 0.25% | – |
| NBIX | New | NEUROCRINE BIOSCIENCES INC | $50,400,000 | – | 448,000 | +100.0% | 0.25% | – |
| Buy | ROIVANT SCIENCES LTD | $45,007,712 | +89.6% | 3,853,400 | +63.6% | 0.23% | +83.7% | |
| MRTX | New | MIRATI THERAPEUTICS INC | $43,603,560 | – | 1,001,000 | +100.0% | 0.22% | – |
| DEN | New | DENBURY INC | $41,654,250 | – | 425,000 | +100.0% | 0.21% | – |
| New | ZTO EXPRESS CAYMAN INCnote 1.500% 9/0 | $33,941,250 | – | 35,000,000 | +100.0% | 0.17% | – | |
| IONS | Buy | IONIS PHARMACEUTICALS INC | $32,976,720 | +15974.4% | 727,000 | +14440.0% | 0.16% | +16400.0% |
| CRL | New | CHARLES RIV LABS INTL INC | $28,613,080 | – | 146,000 | +100.0% | 0.14% | – |
| X | New | UNITED STATES STL CORP NEW | $20,624,800 | – | 635,000 | +100.0% | 0.10% | – |
| IMVT | New | IMMUNOVANT INC | $19,348,560 | – | 504,000 | +100.0% | 0.10% | – |
| NATI | New | NATIONAL INSTRS CORP | $15,799,300 | – | 265,000 | +100.0% | 0.08% | – |
| ESTE | New | EARTHSTONE ENERGY INCcl a | $12,525,139 | – | 618,831 | +100.0% | 0.06% | – |
| TAL | New | TAL EDUCATION GROUPsponsored ads | $12,435,150 | – | 1,365,000 | +100.0% | 0.06% | – |
| New | SOLENO THERAPEUTICS INC | $11,449,880 | – | 388,000 | +100.0% | 0.06% | – | |
| CD | New | CHINDATA GROUP HLDGS LTDads | $10,790,000 | – | 1,300,000 | +100.0% | 0.05% | – |
| CRNX | New | CRINETICS PHARMACEUTICALS IN | $10,763,025 | – | 361,904 | +100.0% | 0.05% | – |
| LBPH | Buy | LONGBOARD PHARMACEUTICALS IN | $8,676,380 | +18.2% | 1,560,500 | +56.0% | 0.04% | +13.2% |
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $7,381,776 | +102.3% | 194,053 | +384.5% | 0.04% | +94.7% |
| GOSS | New | GOSSAMER BIO INC | $5,105,291 | – | 6,130,272 | +100.0% | 0.03% | – |
| NDAQ | New | NASDAQ INC | $4,980,475 | – | 102,500 | +100.0% | 0.02% | – |
| VERV | New | VERVE THERAPEUTICS INC | $2,801,745 | – | 211,293 | +100.0% | 0.01% | – |
| TVTX | New | TRAVERE THERAPEUTICS INC | $2,427,362 | – | 271,517 | +100.0% | 0.01% | – |
| FBRX | New | FORTE BIOSCIENCES INC | $1,198,521 | – | 1,810,455 | +100.0% | 0.01% | – |
| SAGE | New | SAGE THERAPEUTICS INC | $880,824 | – | 42,800 | +100.0% | 0.00% | – |
| FOLD | New | AMICUS THERAPEUTICS INC | $194,560 | – | 16,000 | +100.0% | 0.00% | – |
| CHE | New | CHEMED CORP NEW | $207,880 | – | 400 | +100.0% | 0.00% | – |
| AKRO | New | AKERO THERAPEUTICS INC | $202,320 | – | 4,000 | +100.0% | 0.00% | – |
| HIMS | New | HIMS & HERS HEALTH INC | $264,180 | – | 42,000 | +100.0% | 0.00% | – |
| KRYS | New | KRYSTAL BIOTECH INC | $232,000 | – | 2,000 | +100.0% | 0.00% | – |
| HQY | New | HEALTHEQUITY INC | $204,540 | – | 2,800 | +100.0% | 0.00% | – |
| New | AEON BIOPHARMA INC*w exp 07/21/202 | $7,499 | – | 49,995 | +100.0% | 0.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MICROSOFT CORP | 41 | Q3 2023 | 3.7% |
| RADIUS HEALTH INC | 33 | Q2 2022 | 1.7% |
| GRIFOLS S A | 33 | Q4 2021 | 0.9% |
| ALPHABET INC | 32 | Q3 2023 | 4.2% |
| SPDR S&P 500 ETF TR | 31 | Q3 2023 | 25.3% |
| VISA INC | 30 | Q3 2023 | 2.9% |
| WABTEC CORP | 27 | Q3 2023 | 3.6% |
| EXELIXIS INC | 27 | Q3 2023 | 2.8% |
| ELEVANCE HEALTH INC | 26 | Q3 2023 | 2.6% |
| SAVARA INC | 26 | Q3 2023 | 0.3% |
View FARALLON CAPITAL MANAGEMENT LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Atento S.A. | March 15, 2023 | 2,230,357 | 15.4% |
| Metals Acquisition Corp | February 07, 2023 | 2,489,700 | 9.4% |
| Inflection Point Acquisition Corp. | February 06, 2023 | 1,900,000 | 5.8% |
| AMYRIS, INC. | February 24, 2022 | 1,068,904 | 0.3% |
| Swiftmerge Acquisition Corp. | February 14, 2022 | 291,060 | 1.3% |
| Caribou Biosciences, Inc. | February 11, 2022 | 2,428,150 | 4.0% |
| ENANTA PHARMACEUTICALS INC | February 11, 2022 | 287,000 | 1.4% |
| Protagonist Therapeutics, Inc | February 11, 2022 | 387,051 | 0.8% |
| Solid Power, Inc. | February 11, 2022 | ? | ? |
| Better Therapeutics, Inc. | February 09, 2022 | 124,065 | 0.5% |
View FARALLON CAPITAL MANAGEMENT LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR | 2024-02-14 |
| 13F-HR/A | 2024-02-12 |
| SC 13G/A | 2024-02-01 |
| SC 13G/A | 2024-01-23 |
View FARALLON CAPITAL MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.